Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: A proof of concept study

Tsushima, Kenji; Yamaguchi, Koichi; Kono, Yuta; Yokoyama, Toshiki; Kubo, Keishi; Matsumura, Takuma; Ichimura, Yasunori; Abe, Mitsuhiro; Terada, Jiro; Tatsumi, Koichiro

doi:10.1016/j.pupt.2014.04.008

Cited by 66 publications

(56 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 11 citations were identified, and after screening, five publications were included in the review [9][10][11][12][13]. All studies were reported from Japan.…”

Section: Search and Selection Resultsmentioning

confidence: 99%

“…Therefore, rhTM may be superior than anticoagulant such as warfarin to AE-IPF in which inflammation is associated with clinical condition. Tsushima mentioned the anti-inflammatory action by rhTM contributed to the efficacy in AE-IPF [13]. It has been reported about its side effect that no significant difference was observed in severe hemorrhagic complication between rhTM group and control group [6].…”

Section: Discussionmentioning

confidence: 97%

“…Of enrolled five studies, three were prospective, historical control studies [9,10,13] and two were retrospective studies (11,12). The five studies recruited a total of 77 patients receiving rhTM treatment (rhTM group).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…For rhTM group, the administration of rhTM was started at a dose of 0.06 mg/kg/day once daily for six days, in four of five studies [10][11][12][13]. The treatment with rhTM was followed by continuous intravenous infusion of low-molecular weight heparin (LMWH) (750,000 IU/kg/day) in one study [11].…”

Section: Treatment Regimenmentioning

confidence: 99%

“…Mortality at 28 days or one month was evaluated in all three prospective studies, and was lower in the rhTM group than in non-rhTM group (7/20 (35%) vs 5/6 (83%), 2/11 (18%) vs 6/11 (54%) and 3/10 (30%) vs 6/13 (46%), respectively) [9,10,13]. As shown in Figure 1, the pooled 1-month mortality was significantly lower in rhTM group (Odds Ratio (OR): 0.25 (95% CI, 0.08-0.77)).…”

Section: Mortalitymentioning

confidence: 99%

See 4 more Smart Citations

Thrombomodulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Ichimura¹,

Tsushima²,

Matsumura³

et al. 2017

Chron Obstruct Pulmon Dis

Self Cite

View full text Add to dashboard Cite

Background: Acute exacerbation (AE) is known as a leading cause of morbidity and mortality in chronic fibrosing group includes idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). There is no standardizes drug therapy with comparative studies. The clinical application of recombinant human soluble thrombomodulin (rhTM) has recently been expected against AE-IPF/NSIP, however, the impact of rhTM remains unestablished. Thus, this review assessed the impact of rhTM on mortality in patients with AE-IPF/NSIP.

show abstract

“…A total of 11 citations were identified, and after screening, five publications were included in the review [9][10][11][12][13]. All studies were reported from Japan.…”

Section: Search and Selection Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 97%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Treatment Regimenmentioning

confidence: 99%

Section: Mortalitymentioning

confidence: 99%

See 3 more Smart Citations

Thrombomodulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Ichimura¹,

Tsushima²,

Matsumura³

et al. 2017

Chron Obstruct Pulmon Dis

Self Cite

View full text Add to dashboard Cite

show abstract

Pharmacologic Treatment of IPF

Smargiassi

Pasciuto

Conte

et al. 2018

Respiratory Medicine

View full text Add to dashboard Cite

Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Lee¹,

Collard²

2018

Respiratory Medicine

View full text Add to dashboard Cite

A 70-year-old-woman with idiopathic pulmonary fibrosis (IPF) presented with worsening dyspnea, nonproductive cough and increasing home oxygen requirements over a 24 h period.IPF had been previously diagnosed in accordance with American Thoracic Society guidelines (1); having a consistent clinical presentation, absence of alternative diagnosis and a definite usual interstitial pneumonia pattern on chest computed tomography (CT). History included hemochromatosis, diabetes, hypertension and osteoarthritis. Pirfenidone was initiated two months before presentation. Physical examination revealed clubbing and bilateral basal-predominant fine crackles, consistent with IPF without evidence of heart failure.A routine CT scan of the chest had been performed two days before developing increased dyspnea (Figure 1A) and a repeat contrastenhanced CT chest scan at the time of hospitalization (Figure 1B). There was interval development of diffuse ground-glass opacities (GGO) in both lungs without evidence of pulmonary embolism. Sputum cultures and a nasopharyngeal swab (for polymerase chain reaction) failed to identify bacterial, fungal or viral infection. Bronchoscopy could not be performed due to high oxygen requirements.Treatment with 1 g of intravenous methylprednisilone was given for three days, followed by 50 mg of prednisone. Dyspnea and oxygen requirements returned to baseline. Repeat imaging at one week (Figure 1C) showed interval resolution of GGO. The patient was discharged home with plans to taper off her prednisone over a four-week period.

show abstract

Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: A proof of concept study

Cited by 66 publications

References 26 publications

Thrombomodulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Thrombomodulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Pharmacologic Treatment of IPF

Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Contact Info

Product

Resources

About